Advised Beijing SinoHytec Co., Ltd. on its Global Offering

On 12 January 2023, Beijing SinoHytec Co., Ltd. (“SinoHytec”), a company listed on the SSE STAR Market (Stock code：688339.SH), successfully listed on the Main Board of The Stock Exchange of Hong Kong Limited (“Stock Exchange”) (Stock code: 2402) and became the first SSE STAR Market listed company to be listed on the Stock Exchange in 2023.

SinoHytec is a leading provider of fuel cell systems in China, focusing on the design, development and manufacture of fuel cell systems and stacks mainly for commercial vehicles, such as buses and trucks. SinoHytec ranked first in the PRC fuel cell system market in terms of the total power output of fuel cell systems sold in 2021, with a market share of 27.8%. As of June 30, 2022, SinoHytec’s fuel cell systems were installed on 80 models of fuel cell vehicles that are featured in the MIIT New Energy Vehicle Catalogs, ranking us first in the industry.

DeHeng Law Offices, acting as legal advisors to the issuer as to PRC laws, formed a project team led by partners Zhang Jiejun and Qiu Ru, and supported by Peng Hong, Gu Yatao, Liu Yuanjun and Wang Xin; Chungs Lawyers (in association with DeHeng Law Offices), acting as legal advisors to the issuer as to Hong Kong laws, also formed a project team to fully participate in and facilitate the project.

Both project teams worked closely and actively with SinoHytec, its sponsors and other professional parties to provide professional, comprehensive and efficient legal services for this project.

Advised Honworld Group Limited on the Resumption of Trading on the Stock Exchange

Chungs Lawyers (in association with DeHeng Law Offices) has advised Honworld Group Limited (Stock Code: 2226) (the “Company”, together with its subsidiaries, the “Group”) to successfully resume trading of its shares on the Stock Exchange of Hong Kong Limited (the “Stock Exchange”). The Group is one of the leading manufacturers of condiment products in the PRC. Trading in the Company’s shares had been suspended with effect from 30 March 2021. Pursuant to the resumption guidance (the “Resumption Guidance”) imposed by the Stock Exchange, the resumption conditions that the Company should satisfy include the following conditions:

• žto demonstrate the Company’s compliance with Rule 13.24 of the Rules Governing the Listing of Securities on the Stock Exchange (the “Listing Rules”), which provides that the Company shall carry out its business with a sufficient level of operations and assets of sufficient value to support its operations;

• žto conduct an independent investigation into the relevant matters, announce the investigation findings, assess and announce the impact on the Company’s operation and financial position, and take appropriate remedial actions;

• žto demonstrate that there is no reasonable regulatory concern about management integrity and/or the integrity of any persons with substantial influence over the Company’s management and operations, which may pose a risk to investors and damage market confidence;

• žto demonstrate that the directors of the Company meet a standard of competence commensurate with their position as directors of a listed issuer to fulfill duties of skill, care and diligence as required under Rule 3.09 of the Listing Rules; and

• žto conduct an independent internal control review and demonstrate that the Company has in place adequate internal controls and procedures to meet obligations under the Listing Rules.

Chungs Lawyers worked closely with the Company team and the Company’s professional advisers to assist the Company in formulating the appropriate approach on fulfilling the Resumption Guidance. Chungs Lawyers assisted in communicating with the regulators, advising on the scope of the independent forensic investigations and internal control review, handling legal and regulatory issues encountered by the Company in the process of resumption, and providing training to the Company’s directors and senior management on the Listing Rules.

Advised Guanze Medical Information Industry (Holding) Co., Ltd. on its Global Offering

On 29 December 2022, Guanze Medical Information Industry (Holding) Co., Ltd. (“Guanze”) successfully listed on the Main Board of The Stock Exchange of Hong Kong Limited (Stock code: 2427).

In this project, Chungs Lawyers (in association with DeHeng Law Offices) acts as the Hong Kong legal counsel to the sole sponsor, Southwest Securities (HK) Capital Limited, and fully participates in and promotes the project.

Immediately upon completion of the global offering, the market capitalisation of Guanze exceeds HK$500 million.

Guanze is a medical imaging solutions provider, principally engaged in providing medical imaging film products and medical imaging cloud services in Shandong Province. In respect of the medical imaging film products business, Guanze engages in the distribution of medical imaging film products from international brands, and the sale of its self-branded medical imaging film products. In respect of the medical imaging cloud services business, Guanze was the third largest medical imaging cloud

services supplier in Shandong Province with a market share of approximately 4.7%, in terms of sales revenue in 2021.

Chungs Lawyers (in association with DeHeng Law Offices) worked closely and actively with other professional parties to provide professional, comprehensive and efficient legal services for this project.